-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, DBV Technologies Submits BLA To FDA For VIASKIN Peanut Patch In Children Aged 4-7 With Peanut Allergy, Requests Priority Review

Benzinga·09/30/2026 07:43:07
Listen to the news

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

  • The BLA is supported by the results from the successful Phase 3 VITESSE trial – the largest immunotherapy clinical trial to date for this population. 
  • DBV has requested Priority Review of the BLA.